{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:56:06Z","timestamp":1793044566685,"version":"4.5.0"},"reference-count":152,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Research Foundation (NRF) of South Africa"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1002\/jps.24322","type":"journal-article","created":{"date-parts":[[2015,1,5]],"date-time":"2015-01-05T23:22:54Z","timestamp":1420500174000},"page":"1213-1229","source":"Crossref","is-referenced-by-count":46,"title":["A Review of the Potential Role of Nano-Enabled Drug Delivery Technologies in Amyotrophic Lateral Sclerosis: Lessons Learned from Other Neurodegenerative Disorders"],"prefix":"10.1016","volume":"104","author":[{"given":"Zamanzima","family":"Mazibuko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya E.","family":"Choonara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa C.","family":"Du Toit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viness","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1002\/jps.24322_bb0005","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1471-4159.2010.06683.x","article-title":"Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS","volume":"113","author":"Gros-Louis","year":"2010","journal-title":"J Neurochem"},{"key":"10.1002\/jps.24322_bb0010","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1136\/jnnp.57.8.886","article-title":"Motor neuron disease","volume":"57","author":"Leigh","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/jps.24322_bb0015","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0022-510X(98)00193-2","article-title":"Diagnosis of amyotrophic lateral sclerosis","volume":"160","author":"Rowland","year":"1998","journal-title":"J Neurol Sci"},{"key":"10.1002\/jps.24322_bb0020","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJM200105313442207","article-title":"Amyotrophic lateral sclerosis","volume":"344","author":"Rowland","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1002\/jps.24322_bb0025","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1086\/425287","article-title":"A mutation in the vehicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis","volume":"75","author":"Nishimura","year":"2004","journal-title":"Am J Hum Genet"},{"key":"10.1002\/jps.24322_bb0030","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3109\/17482968.2011.636049","article-title":"No evidence for a large difference in ALS frequency in populations of African and European origin: A population based study in inner city London","volume":"13","author":"Rojas-Garcia","year":"2012","journal-title":"Amyotroph Lateral Scler"},{"issue":"19","key":"10.1002\/jps.24322_bb0035","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1212\/WNL.0b013e3181a55f7b","article-title":"Reduced frequency of ALS in an ethnically mixed population: A population-based mortality study","volume":"72","author":"Zaldivar","year":"2009","journal-title":"Neurology"},{"key":"10.1002\/jps.24322_bb0040","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.1165942","article-title":"Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6","volume":"323","author":"Vance","year":"2009","journal-title":"Science"},{"key":"10.1002\/jps.24322_bb0045","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1136\/bmj.318.7191.1118","article-title":"Motor neurone disease","volume":"18","author":"Shaw","year":"1999","journal-title":"BMJ"},{"key":"10.1002\/jps.24322_bb0050","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/17482960801900032","article-title":"A systematic review of antioxidant treatment for amyotropic lateral sclerosis\/motor neuron disease","volume":"9","author":"Orrell","year":"2008","journal-title":"Amyotroph Lateral Scler"},{"key":"10.1002\/jps.24322_bb0055","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1089\/ars.2006.8.1865","article-title":"Redefining oxidative stress","volume":"8","author":"Jones","year":"2006","journal-title":"Antioxid Redox Signal"},{"key":"10.1002\/jps.24322_bb0060","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1113\/expphysiol.1997.sp004024","article-title":"Oxidative stress: Oxidants and antioxidants","volume":"82","author":"Sies","year":"1997","journal-title":"Exp Physiol"},{"key":"10.1002\/jps.24322_bb0065","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.freeradbiomed.2009.11.018","article-title":"Oxidative stress in ALS: Key role in motor neuron injury and therapeutic target","volume":"48","author":"Barber","year":"2010","journal-title":"Free Radic Biol Med"},{"key":"10.1002\/jps.24322_bb0070","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0165-5728(01)00246-6","article-title":"Expression and function of inducible nitric oxide synthase in neurons","volume":"114","author":"Heneka","year":"2001","journal-title":"J Neuroimmunol"},{"key":"10.1002\/jps.24322_bb0075","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0891-5849(98)00095-1","article-title":"Oxidative chemistry of nitric oxide: The roles of superoxide, peroxynitrite, and carbon dioxide","volume":"25","author":"Squadrito","year":"1998","journal-title":"Free Radic Biol Med"},{"key":"10.1002\/jps.24322_bb0080","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/carcin\/21.3.361","article-title":"Oxyradicals and DNS damage","volume":"21","author":"Marnett","year":"2000","journal-title":"Carcinogenesis"},{"key":"10.1002\/jps.24322_bb0085","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0003-9861(92)90431-U","article-title":"Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase","volume":"298","author":"Ischiropoulos","year":"1992","journal-title":"Arch Biochem Biophys"},{"key":"10.1002\/jps.24322_bb0090","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.bbadis.2006.03.008","article-title":"Oxidative stress in ALS: A mechanism for neurodegeneration and a therapeutic target","volume":"1762","author":"Barber","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1002\/jps.24322_bb0095","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1111\/j.1471-4159.1993.tb07478.x","article-title":"Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis","volume":"61","author":"Bowling","year":"1993","journal-title":"J Neurochem"},{"issue":"8","key":"10.1002\/jps.24322_bb0100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0166-2236(93)90109-Y","article-title":"Synthesis of nitric oxide in CNS glial cells","volume":"16","author":"Murphy","year":"1993","journal-title":"Trends Neurosci"},{"key":"10.1002\/jps.24322_bb0105","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1046\/j.1471-4159.1999.0722415.x","article-title":"Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis","volume":"72","author":"Almer","year":"1999","journal-title":"J Neurochem"},{"key":"10.1002\/jps.24322_bb0110","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1046\/j.1471-4159.1997.69031196.x","article-title":"Oxidative DNA damage in the parkinsonian brain: An apparent selective increase in 8-hydroxyguanine levels in substantia nigra","volume":"69","author":"Alam","year":"1997","journal-title":"J Neurochem"},{"key":"10.1002\/jps.24322_bb0115","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1046\/j.1471-4159.1997.69052064.x","article-title":"Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis","volume":"69","author":"Ferrante","year":"1997","journal-title":"J Neurochem"},{"key":"10.1002\/jps.24322_bb0120","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ana.410440518","article-title":"Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients","volume":"44","author":"Pedersen","year":"1998","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1002\/jps.24322_bb0125","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/ana.410440419","article-title":"Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis","volume":"44","author":"Smith","year":"1998","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1002\/jps.24322_bb0130","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1517\/14728214.12.2.229","article-title":"Emerging disease-modifying therapies for the treatment of motor neuron disease\/amyotrophic lateral sclerosis","volume":"12","author":"Bedlack","year":"2007","journal-title":"Expert Opin Emerg Drugs"},{"issue":"10","key":"10.1002\/jps.24322_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003895","article-title":"ALS-associated FUS mutations result in compromised FUS alternative splicing and autoregulation","volume":"9","author":"Zhou","year":"2013","journal-title":"PloS Genet"},{"key":"10.1002\/jps.24322_bb0140","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1474-4422(12)70043-1","article-title":"Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: A cross-sectional study","volume":"11","author":"Majounie","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1002\/jps.24322_bb0145","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1126\/science.1232927","article-title":"The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD\/ALS","volume":"339","author":"Mori","year":"2013","journal-title":"Science"},{"key":"10.1002\/jps.24322_bb0150","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","article-title":"Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS","volume":"72","author":"DeJesus-Hemandez","year":"2011","journal-title":"Neuron"},{"key":"10.1002\/jps.24322_bb0155","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0891-5849(02)00905-X","article-title":"Superoxide dismutase multigene family: A comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression","volume":"33","author":"Zelko","year":"2002","journal-title":"Free Radic Biol Med"},{"key":"10.1002\/jps.24322_bb0160","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/jhered\/93.2.119","article-title":"Structure, chromosomal location, and analysis of the canine Cu\/Zn superoxide dismutase (SOD1) gene","volume":"93","author":"Green","year":"2002","journal-title":"J Hered"},{"key":"10.1002\/jps.24322_bb0165","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1006\/nbdi.2001.0443","article-title":"Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues","volume":"8","author":"Watanabe","year":"2001","journal-title":"Neurobiol Dis"},{"key":"10.1002\/jps.24322_bb0170","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1126\/science.281.5384.1851","article-title":"Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1","volume":"281","author":"Bruijn","year":"1998","journal-title":"Science"},{"issue":"5","key":"10.1002\/jps.24322_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020427","article-title":"Colocalization of 14\u20133\u20133 proteins with SOD1 in lewy body-like hyaline inclusions in familial amyotrophic lateral sclerosis cases and the animal model","volume":"6","author":"Okamoto","year":"2011","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1002\/jps.24322_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001677","article-title":"SOD1 and amyotrophic lateral sclerosis: Mutations and oligomerization","volume":"3","author":"Banci","year":"2008","journal-title":"Plos ONE"},{"key":"10.1002\/jps.24322_bb0185","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ana.21392","article-title":"TDP-43 mutation in familial amyotrophic lateral sclerosis","volume":"63","author":"Yokoseki","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1002\/jps.24322_bb0190","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.21147","article-title":"Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations","volume":"61","author":"Mackenzie","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1002\/jps.24322_bb0195","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1089\/ars.2009.2444","article-title":"Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis","volume":"11","author":"Foran","year":"2009","journal-title":"Antioxid Redox Signal"},{"key":"10.1002\/jps.24322_bb0200","first-page":"1","article-title":"Glutamate pathway implication in amyotrophic lateral sclerosis: What is the signal in the noise?","volume":"4","author":"Le Verche","year":"2011","journal-title":"J Recep Ligand Channel Res"},{"key":"10.1002\/jps.24322_bb0205","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/mus.10186","article-title":"Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis","volume":"26","author":"Heath","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1002\/jps.24322_bb0210","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/1097-4547(20010301)63:5<377::AID-JNR1032>3.0.CO;2-#","article-title":"N-methyl-D-Aspartate receptor-mediated mitochondrial Ca2+ overload in acute excitotoxic motor neuron death: A mechanism distinct from chronic neurotoxicity after ca2+ influx","volume":"63","author":"Urushitani","year":"2001","journal-title":"J Neurosci Res"},{"key":"10.1002\/jps.24322_bb0215","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1523\/JNEUROSCI.20-01-00123.2000","article-title":"AMPA receptor calcium permeability, GluR2 expression, and selected motoneuron vulnerability","volume":"20","author":"Vandenberghe","year":"2000","journal-title":"J Neurosci"},{"key":"10.1002\/jps.24322_bb0220","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0022-510X(02)00339-8","article-title":"Low concentrations of glutamate induce apoptosis in cultured neurons: Implications for amyotrophic lateral sclerosis","volume":"206","author":"Cid","year":"2003","journal-title":"J Neurol Sci"},{"issue":"19","key":"10.1002\/jps.24322_bb0225","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1093\/hmg\/ddg267","article-title":"Increased expression of the glial glutamate transporter EAAfx2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice","volume":"12","author":"Guo","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1002\/jps.24322_bb0230","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000080049","article-title":"Neurotrophic factors and amyotrophic lateral sclerosis","volume":"1","author":"Ekestern","year":"2004","journal-title":"Neurodegener Dis"},{"key":"10.1002\/jps.24322_bb0235","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1006\/nbdi.1999.0253","article-title":"Preclinical testing of neuroprotective neurotrophic factors in a model of chronic motor neuron degeneration","volume":"6","author":"Corse","year":"1999","journal-title":"Neurobiol Dis"},{"key":"10.1002\/jps.24322_bb0240","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nn1360","article-title":"Treatment of motorneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS","volume":"8","author":"Storkebaum","year":"2005","journal-title":"Nat Neurosci"},{"key":"10.1002\/jps.24322_bb0245","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/146608201300079364","article-title":"A double-blind, placebo-controlled randomised clinical trial of \u201ctocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis","volume":"2","author":"Desnuelle C, Dib M, Garrel C, ALS Riluzole-tocopherol study group","year":"2001","journal-title":"Amyotroph Lateral Scler Other Mot Neuron Disord"},{"key":"10.1002\/jps.24322_bb0250","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ana.21743","article-title":"Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III","volume":"66","author":"Kaufmann","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1002\/jps.24322_bb0255","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/14660820050515197","article-title":"A phase I\/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis","volume":"1","author":"Ochs","year":"2000","journal-title":"Amyotroph Lateral Scler Other Mot Neuron Disord"},{"key":"10.1002\/jps.24322_bb0260","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1212\/01.wnl.0000335970.78664.36","article-title":"Subcutaneous IGF-1 is not beneficial in 2-year ALS trial","volume":"71","author":"Sorenson","year":"2008","journal-title":"Neurology"},{"key":"10.1002\/jps.24322_bb0265","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1212\/WNL.47.5.1329","article-title":"Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis","volume":"47","author":"Miller","year":"1996","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/jps.24322_bb0270","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1212\/WNL.36.2.146","article-title":"Controlled trial of thyrotropin releasing hormone in amyotrophic lateral sclerosis","volume":"36","author":"Brooke","year":"1986","journal-title":"Neurology"},{"key":"10.1002\/jps.24322_bb0275","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14660820410019602","article-title":"Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: Results of two phase III trials","volume":"5","author":"Meininger","year":"2004","journal-title":"Amyotroph Lateral Scler Other Mot Neuron Disord"},{"key":"10.1002\/jps.24322_bb0280","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1474-4422(11)70024-2","article-title":"Emerging targets and treatments in amyotrophic lateral sclerosis","volume":"10","author":"Zinman","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1002\/jps.24322_bb0285","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.nbd.2004.06.004","article-title":"Effects of vascular endothelial growth (VEGF) on motor neuron degeneration","volume":"17","author":"Van Den Bosch","year":"2004","journal-title":"Neurobiol Dis"},{"key":"10.1002\/jps.24322_bb0290","unstructured":"An open label, safety and tolerability continuation study of intracerebroventricular administration of sNN0029 to patients with amyotrophic lateral sclerosis. Accessed 30 May, 2013, at: http:\/\/clinicaltrials.gov\/show\/NCT01384162."},{"key":"10.1002\/jps.24322_bb0295","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1086\/597807","article-title":"The antibiotics doxycycline and minocycline inhibit the inflammatory responses to the lyme disease spirochete borrelia burgdorferi","volume":"199","author":"Bernardino","year":"2009","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1002\/jps.24322_bb0300","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1523\/JNEUROSCI.21-08-02580.2001","article-title":"Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia","volume":"21","author":"Tikka","year":"2001","journal-title":"J Neurosci"},{"key":"10.1002\/jps.24322_bb0305","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(07)70270-3","article-title":"Efficacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomised trial","volume":"6","author":"Gordon","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1002\/jps.24322_bb0310","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.2174\/092986710791163939","article-title":"Riluzole, neuroprotection and amyotrophic lateral sclerosis","volume":"17","author":"Cheah","year":"2010","journal-title":"Curr Med Chem"},{"key":"10.1002\/jps.24322_bb0315","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1755-5949.2009.00116.x","article-title":"A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: What have we learnt in the past decade?","volume":"17","author":"Bellingham","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"10.1002\/jps.24322_bb0320","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1111\/j.1460-9568.2008.06211.x","article-title":"Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motorneurons in vitro","volume":"27","author":"Lamanauskas","year":"2008","journal-title":"Eur J Neurosci"},{"key":"10.1002\/jps.24322_bb0325","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1472-8206.1992.tb00109.x","article-title":"Effects of riluzole (2-amino-6-trifluoromethoxy benzothiozole) on striatal neurochemical markers in the rat, with special reference to the dopamine, choline, GABA and glutamate synaptosomal high affinity uptake systems","volume":"6","author":"Samuel","year":"1992","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1002\/jps.24322_bb0330","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s10072-003-0160-9","article-title":"Effect of Riluzole (Rilutek) treatment on plasma amino acid percentages in amyotrophic lateral sclerosis patients","volume":"24","author":"Ilzecka","year":"2003","journal-title":"Neurol Sci"},{"key":"10.1002\/jps.24322_bb0335","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis","volume":"330","author":"Bensimon G, Lacomblez L, Meininger V, The ALS\/riluzole study group","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1002\/jps.24322_bb0340","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1212\/01.wnl.0000338538.18938.9d","article-title":"The need for biomarkers in amyotrophic lateral sclerosis drug development","volume":"72","author":"Wagner","year":"2009","journal-title":"Neurol"},{"key":"10.1002\/jps.24322_bb0345","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/17434470410019942","article-title":"Randomized control trials in ALS: Lessons learned","volume":"5","author":"Mitsumoto","year":"2004","journal-title":"Amyotrophic Lateral Scler Other Motor Neuron Disord"},{"issue":"2","key":"10.1002\/jps.24322_bb0350","doi-asserted-by":"crossref","first-page":"113","DOI":"10.7326\/0003-4819-154-2-201101180-00010","article-title":"Addressing missing data in clinical trials","volume":"154","author":"Fleming","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1002\/jps.24322_bb0355","first-page":"343","article-title":"Strategies for dealing with missing data in clinical trials: From design to analysis","volume":"86","author":"Dziura","year":"2013","journal-title":"Yale J Biol Med"},{"key":"10.1002\/jps.24322_bb0360","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1212\/01.wnl.0000201182.60750.66","article-title":"A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS","volume":"66","author":"Levy","year":"2006","journal-title":"Neurology"},{"key":"10.1002\/jps.24322_bb0365","series-title":"Amyotrophic lateral sclerosis","article-title":"Stem cell application for amyotrophic lateral sclerosis: Growth factor delivery and cell therapy","author":"Suzuki","year":"2012"},{"issue":"3","key":"10.1002\/jps.24322_bb0370","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/jps.22332","article-title":"Synthesis and in vitro evaluation of gabapentin prodrugs that target the human apical sodium- dependent bile acid transporter (hASBT)","volume":"100","author":"Rais","year":"2011","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1002\/jps.24322_bb0375","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4088\/JCP.v64n0216","article-title":"A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder","volume":"64","author":"Amsterdam","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/jps.24322_bb0380","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.nbd.2009.07.028","article-title":"Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain disease","volume":"37","author":"Gabathuler","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1002\/jps.24322_bb0385","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1472-8206.1999.tb00316.x","article-title":"Drug transfer across the blood-brain barrier and improvement of brain delivery","volume":"13","author":"Jolliet-Riant","year":"1999","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1002\/jps.24322_bb0390","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jconrel.2005.07.024","article-title":"Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer\u2019s disease","volume":"108","author":"Roney","year":"2005","journal-title":"J Control Release"},{"key":"10.1002\/jps.24322_bb0395","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1083\/jcb.115.6.1725","article-title":"A cell culture model of the blood-brain barrier","volume":"115","author":"Rubin","year":"1991","journal-title":"J Cell Biol"},{"key":"10.1002\/jps.24322_bb0400","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1039\/B405713A","article-title":"An endothelial and astrocyte co-culture model of the blood-brain barrier utilizing an ultra-thin nanofabricated silicon nitride membrane","volume":"5","author":"Ma","year":"2005","journal-title":"Lab Chip"},{"key":"10.1002\/jps.24322_bb0405","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1749-6632.2009.05108.x","article-title":"Advances in the treatment of neurodegenerative disorders employing nanotechnology","volume":"1184","author":"Modi","year":"2010","journal-title":"Ann NY Acad Sci"},{"issue":"21","key":"10.1002\/jps.24322_bb0410","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2008.19.3789","article-title":"Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: A multi-institutional experience","volume":"27","author":"Angelov","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1002\/jps.24322_bb0415","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3171\/jns.2000.92.4.0599","article-title":"In vivo assessment of the window of barrier opening after osmotic blood\u2013brain barrier disruption in humans","volume":"92","author":"Siegal","year":"2000","journal-title":"J Neurosurg"},{"key":"10.1002\/jps.24322_bb0420","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.coph.2006.06.001","article-title":"Molecular Trojan horses for blood\u2013brain barrier drug delivery","volume":"6","author":"Pardridge","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1002\/jps.24322_bb0425","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","article-title":"Nasal drug delivery\u2014Possibilities, problems and solutions","volume":"87","author":"Illum","year":"2003","journal-title":"J Control Release"},{"issue":"1","key":"10.1002\/jps.24322_bb0430","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1602\/neurorx.2.1.86","article-title":"Blood-brain barrier active efflux transporters: ATP-binding cassette gene family","volume":"2","author":"Loscher","year":"2005","journal-title":"Neurotherapeutics"},{"key":"10.1002\/jps.24322_bb0435","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0169-409X(98)00084-2","article-title":"Carrier-mediated or specialized transport of drugs across the blood\u2013brain barrier","volume":"36","author":"Tsuji","year":"1999","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1002\/jps.24322_bb0440","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2014.00021","article-title":"Blood\u2013CNS barrier impairment in ALS patients versus an animal model","volume":"8","author":"Garbuzova-Davis","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"10.1002\/jps.24322_bb0445","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.brainres.2009.09.018","article-title":"Impaired blood\u2013brain and blood\u2013spinal cord barriers in mutant SOD1-linked ALS rat","volume":"1301","author":"Nicaise","year":"2009","journal-title":"Brain Res"},{"issue":"2","key":"10.1002\/jps.24322_bb0450","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nbd.2012.03.040","article-title":"Selective increase of two ABC drug efflux transporters at the blood- spinal cord barrier suggests induced pharmacoresistance in ALS","volume":"47","author":"Jablonski","year":"2012","journal-title":"Neurobiol Dis"},{"issue":"12","key":"10.1002\/jps.24322_bb0455","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1038\/mt.2008.197","article-title":"Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS","volume":"16","author":"Suzuki","year":"2008","journal-title":"Mol Ther"},{"key":"10.1002\/jps.24322_bb0460","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1182\/blood-2004-04-1559","article-title":"Human mesenchymal stem cells modulate allogeneic immune cell responses","volume":"105","author":"Aggarwal","year":"2005","journal-title":"Blood"},{"key":"10.1002\/jps.24322_bb0465","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10495-011-0679-9","article-title":"Neuroprotective effects of human mesenchymal stem cells on neural cultures exposed to 6-hydroxydopamine: Implications for reparative therapy in Parkinson\u2019s disease","volume":"17","author":"Cova","year":"2012","journal-title":"Apoptosis"},{"key":"10.1002\/jps.24322_bb0470","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1089\/hum.2005.16.509","article-title":"GDNF delivery using human neural progenitor cells in a rat model of ALS","volume":"16","author":"Klein","year":"2005","journal-title":"Hum Gene Ther"},{"key":"10.1002\/jps.24322_bb0475","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1089\/10430349950017536","article-title":"Intramuscular grafts of myoblasts genetically modified to secrete glial cell line-derived neurotrophic factor prevent motor neuron loss and disease progression in a mouse model of familial amytrophic lateral sclerosis","volume":"10","author":"Mohajeri","year":"1999","journal-title":"Hum Gene Ther"},{"issue":"6","key":"10.1002\/jps.24322_bb0480","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nm0696-696","article-title":"Intrathecal delivery of CTNF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients","volume":"2","author":"Aebischer","year":"1996","journal-title":"Nat Med"},{"issue":"10","key":"10.1002\/jps.24322_bb0485","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1073\/pnas.0600236103","article-title":"Ciliary neurotrophic factor (CNTF) for human retinal degeneration: Phase I trial of CNTF delivered by encapsulated cell intraocular implants","volume":"103","author":"Sieving","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1002\/jps.24322_bb0490","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/bit.21822","article-title":"Poly(lactic- co-glycolic acid) nanospheres and microspheres for short- and longterm delivery of bioactive ciliary neurotrophic factor","volume":"100","author":"Nkansah","year":"2008","journal-title":"Biotechnol Bioeng"},{"key":"10.1002\/jps.24322_bb0495","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s13311-011-0068-7","article-title":"Stem cell transplantation for motor neuron disease: Current approaches and future perspectives","volume":"8","author":"Gowing","year":"2011","journal-title":"Neurotherapeutics"},{"key":"10.1002\/jps.24322_bb0500","series-title":"Handbook on nanoscience, engineering and technology","first-page":"3.1","author":"Roco","year":"2007"},{"key":"10.1002\/jps.24322_bb0505","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1016\/j.biomaterials.2003.09.087","article-title":"Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain","volume":"25","author":"Sun","year":"2004","journal-title":"Biomaterials"},{"key":"10.1002\/jps.24322_bb0510","first-page":"445","article-title":"Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles","volume":"6","author":"Tian","year":"2011","journal-title":"Int J Nanomed"},{"key":"10.1002\/jps.24322_bb0515","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1039\/c2nr30278k","article-title":"Efficient inhibition of colorectal peritoneal carcinomatosis by drug loaded micelles in thermosensitive hydrogel composites","volume":"4","author":"Gong","year":"2012","journal-title":"Nanoscale"},{"key":"10.1002\/jps.24322_bb0520","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.taap.2006.02.009","article-title":"Intracranial drug-delivery scaffolds: Biocompatibility evaluation of sucrose acetate isobutyrate gels","volume":"215","author":"Lee","year":"2006","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1002\/jps.24322_bb0525","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2174\/156802609787521571","article-title":"Recent advances in medicinal chemistry and pharmaceutical technology-strategies for drug delivery to the brain","volume":"9","author":"Denora","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"10.1002\/jps.24322_bb0530","first-page":"265","article-title":"Blood-brain barrier \u2013 its implication in drug transport: Novel strategies in drug delivery to the brain","volume":"1","author":"Radhika","year":"2011","journal-title":"Int Pharm Biol Sci"},{"key":"10.1002\/jps.24322_bb0535","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0169-409X(03)00041-3","article-title":"Poly (alkylcyanoacrylates) as biodegradable materials for biomedical applications","volume":"55","author":"Vauthier","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1002\/jps.24322_bb0540","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(07)60944-1","article-title":"Amyotrophic lateral sclerosis","volume":"369","author":"Mitchell","year":"2007","journal-title":"Lancet"},{"key":"10.1002\/jps.24322_bb0545","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1002\/jps.21270","article-title":"Nanovehicular intracellular delivery systems","volume":"97","author":"Prokop","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.24322_bb0550","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1755-5949.2010.00199.x","article-title":"Nanoparticulate systems for drug delivery and targeting to the central nervous system","volume":"17","author":"Craparo","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"10.1002\/jps.24322_bb0555","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.foodhyd.2012.04.010","article-title":"Microstructure and physico-chemical evaluation of nano-emulsion-based antimicrobial peptides embedded in bioactive packaging films","volume":"29","author":"Imran","year":"2012","journal-title":"Food Hydrocolloids"},{"issue":"3","key":"10.1002\/jps.24322_bb0560","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ejpb.2007.04.005","article-title":"Liposomes for drug delivery to the lungs by nebulisation","volume":"67","author":"Zaru","year":"2007","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1002\/jps.24322_bb0565","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1007\/s11051-013-1704-4","article-title":"Synthesis and upconversion luminescence properties of YFg:Yb3+\/Er3+ hollow nanofibers derived from Y2O3: Yb3+\/Er3+ hollow nanofibers","volume":"15","author":"Li","year":"2013","journal-title":"J Nanopart Res"},{"key":"10.1002\/jps.24322_bb0570","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0266-3538(03)00178-7","article-title":"A review on polymer nanofibers by electrospinning and their application in nanocomposites","volume":"63","author":"Huang","year":"2003","journal-title":"Compos Sci Technol"},{"key":"10.1002\/jps.24322_bb0575","first-page":"895","article-title":"Nanobubbles for enhanced ultrasound imaging of tumours","volume":"7","author":"Yin","year":"2012","journal-title":"Int J Nanomed"},{"key":"10.1002\/jps.24322_bb0580","doi-asserted-by":"crossref","first-page":"214505","DOI":"10.1103\/PhysRevLett.101.214505","article-title":"Dynamic equilibrium mechanism for surface nanobubble stabilisation","volume":"101","author":"Brenner","year":"2008","journal-title":"Phys Rev Lett"},{"key":"10.1002\/jps.24322_bb0585","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.addr.2012.02.002","article-title":"Polymer nanogels: A versatile nanoscopic drug delivery platform","volume":"64","author":"Chacko","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"10.1002\/jps.24322_bb0590","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1021\/nl0155126","article-title":"Highly luminescent monodisperse CdSe and CdSe\/ZnS nanocrystals synthesized in a hexadecylamine-trioctylphosphine oxide- trioctylphospine mixture","volume":"1","author":"Talapin","year":"2001","journal-title":"Nano Lett"},{"key":"10.1002\/jps.24322_bb0595","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1088\/0957-4484\/14\/7\/201","article-title":"Biological applications of colloidal nanocrystals","volume":"14","author":"Parak","year":"2003","journal-title":"Nanotechnology"},{"key":"10.1002\/jps.24322_bb0600","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cap.2007.04.042","article-title":"Polymeric nanomicelles as drug carrier using polyethylene glycol and polytrimethylene carbonate linear and star-shaped block polymer","volume":"8","author":"Kim","year":"2008","journal-title":"Curr Appl Phys"},{"key":"10.1002\/jps.24322_bb0605","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.colsurfa.2007.05.078","article-title":"Polymeric nanomicelles using poly(ethylene glycol) and poly(trimethylene carbonate) diblock copolymers as a carrier drug","volume":"313\u2013314","author":"Hyun","year":"2008","journal-title":"Colloids Surf A Physicochem Eng Aspects"},{"key":"10.1002\/jps.24322_bb0610","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1021\/nn900813b","article-title":"Ultrasensitive and highly selective detection of Alzheimer\u2019s disease biomarker using two-photon Rayleigh scattering properties of gold nanoparticles","volume":"9","author":"Neely","year":"2009","journal-title":"ACS Nano"},{"key":"10.1002\/jps.24322_bb0615","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1021\/nl0516862","article-title":"Nanoparticle-mediated local and remote manipulation of protein aggregation","volume":"6","author":"Kogan","year":"2006","journal-title":"Nano Lett"},{"key":"10.1002\/jps.24322_bb0620","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1196\/annals.1403.015","article-title":"Treatment of neurodegenerative disorders with radical nanomedicine","volume":"1122","author":"Singh","year":"2007","journal-title":"Ann NY Acad Sci"},{"key":"10.1002\/jps.24322_bb0625","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/240146","article-title":"Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems","volume":"2012","author":"Cacciatore","year":"2012","journal-title":"Oxid Med Cell Longev"},{"key":"10.1002\/jps.24322_bb0630","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/1567-1364.12045","article-title":"The involvement of GSH in the activation of human Sod1 linked to FALS in chronologically aged yeast cells","volume":"13","author":"Brasil","year":"2013","journal-title":"FEMS Yeast Res"},{"key":"10.1002\/jps.24322_bb0635","first-page":"251","article-title":"Neural tissue engineering of the CNS using hydrogels","volume":"87B","author":"Nisbet","year":"2008","journal-title":"Appl Biomater"},{"key":"10.1002\/jps.24322_bb0640","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jconrel.2011.02.022","article-title":"Odorranalectin-conjugated nanoparticles: Preparation brain delivery and pharmacodynamic study on Parkinson\u2019s disease following intranasal administration","volume":"151","author":"Wen","year":"2011","journal-title":"J Control Release"},{"key":"10.1002\/jps.24322_bb0645","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijpharm.2011.05.062","article-title":"Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: Preparation, characterization and efficacy in parkinson\u2019s disease","volume":"415","author":"Hu","year":"2011","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.24322_bb0650","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3121\/cmr.3.2.93","article-title":"Lactoferrin\u2014A novel bone growth factor","volume":"3","author":"Naot","year":"2005","journal-title":"Clin Med Res"},{"key":"10.1002\/jps.24322_bb0655","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1039\/b902617g","article-title":"Targeting novel integrative nuclear FGFR1 signalling by nanoparticle-mediated gene transfer stimulates neurogenesis in the adult brain","volume":"1","author":"Stachowiak","year":"2009","journal-title":"Integr Biol"},{"key":"10.1002\/jps.24322_bb0660","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/gps.1341","article-title":"Effects of memantine on behavioural symptoms in Alzheimer\u2019s disease patients: An analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies","volume":"20","author":"Gauthier","year":"2005","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1002\/jps.24322_bb0665","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1474-4422(11)70072-2","article-title":"The projected effect of risk factor reduction on Alzheimer\u2019s disease prevalence","volume":"10","author":"Barnes","year":"2011","journal-title":"Lancet Neurol"},{"issue":"13","key":"10.1002\/jps.24322_bb0670","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2165\/00023210-200418130-00001","article-title":"Combination therapy in Alzheimer\u2019s disease: A review of current evidence","volume":"18","author":"Schmitt","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1002\/jps.24322_bb0675","doi-asserted-by":"crossref","first-page":"15437","DOI":"10.1021\/ja8041806","article-title":"Inhibition of amyloid \u03b2 protein fibrillation by polymeric nanoparticles","volume":"130","author":"Cabaleiro-Lago","year":"2008","journal-title":"J Am Chem Soc"},{"key":"10.1002\/jps.24322_bb0680","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejpb.2004.07.009","article-title":"Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer\u2019s and other CNS diseases","volume":"59","author":"Cui","year":"2005","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1002\/jps.24322_bb0685","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S1474-4422(10)70212-X","article-title":"Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson\u2019s disease","volume":"9","author":"Kehagia","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1002\/jps.24322_bb0690","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"5","author":"de Lau","year":"2006","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1002\/jps.24322_bb0695","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/NDT.S2006","article-title":"Current approadiffereeches to the treatment of Parkinson\u2019s disease","volume":"4","author":"Jankovic","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1002\/jps.24322_bb0700","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijpharm.2011.07.036","article-title":"Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery","volume":"419","author":"Trapani","year":"2011","journal-title":"Int J Pharm"},{"issue":"10","key":"10.1002\/jps.24322_bb0705","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3727\/096368909X12483162196881","article-title":"Compacted DNA nanoparticle gene transfer of GDNF to the rat striatum enhances the survival of grafted fetal dopamine neurons","volume":"18","author":"Yurek","year":"2009","journal-title":"Cell Transplant"},{"issue":"1","key":"10.1002\/jps.24322_bb0710","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2217\/nnm.12.105","article-title":"Detection of Alzheimer\u2019s and Parkinson\u2019s disease from exhaled breath using nanomaterial-based sensors","volume":"8","author":"Tisch","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1002\/jps.24322_bb0715","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/jps.24322_bb0720","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/mds.25075","article-title":"The incidence and prevalence of Huntington\u2019s disease: A systematic review and meta-analysis","volume":"27","author":"Pringsheim","year":"2012","journal-title":"Mov Disorders"},{"key":"10.1002\/jps.24322_bb0725","first-page":"S1","article-title":"Huntington\u2019s disease: A clinical review","volume":"19(5)","author":"Gudesblatt","year":"2011","journal-title":"Neurol Rev (Suppl)"},{"key":"10.1002\/jps.24322_bb0730","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1021\/mp3003946","article-title":"Self-assembling modified \u03b2-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: Focus on huntington\u2019s disease","volume":"10","author":"Godinho","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1002\/jps.24322_bb0735","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2217\/nnm.09.67","article-title":"Brain-targeted solid lipid nanoparticles containing riluzole: Preparation, characterization and biodistribution","volume":"5","author":"Bondi","year":"2010","journal-title":"Nanomedicine"},{"key":"10.1002\/jps.24322_bb0740","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4172\/2157-7439.1000135","article-title":"In vitro evaluation of the physicochemical effects of drug loaded carbon nanotubes on toxicity","volume":"3","author":"Chigumbu","year":"2012","journal-title":"J Nanomed Nanotechnol"},{"issue":"4","key":"10.1002\/jps.24322_bb0745","first-page":"244","article-title":"Design and development of Riluzole loaded chitosan nanoparticles by emulsification crosslinking","volume":"4","author":"Shanmukhapuvvada","year":"2012","journal-title":"Int J Pharm Pharm Sci"},{"key":"10.1002\/jps.24322_bb0750","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4236\/anp.2012.13007","article-title":"Lipopolysaccharide modified liposomes for Amyotrophic lateral sclerosis therapy: Efficacy in SOD1 mouse model","volume":"1","author":"Wiley","year":"2012","journal-title":"Adv Nanopart"},{"key":"10.1002\/jps.24322_bb0755","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0168-3659(02)00008-1","article-title":"Biodegradable in situ forming drug delivery systems","volume":"80","author":"Hatefi","year":"2002","journal-title":"J Control Release"},{"key":"10.1002\/jps.24322_bb0760","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.addr.2006.09.020","article-title":"Thermo- and pH-responsive polymers in drug delivery","volume":"58","author":"Schmaljohann","year":"2006","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915301453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915301453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T10:03:17Z","timestamp":1717668197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915301453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":152,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0022354915301453"],"URL":"https:\/\/doi.org\/10.1002\/jps.24322","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}